<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Eosinophilic cellulitis (Wells syndrome)</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Eosinophilic cellulitis (Wells syndrome)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Eosinophilic cellulitis (Wells syndrome)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan I Silverberg, MD, PhD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John A Zic, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 28, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2030912664"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Eosinophilic cellulitis (EC) is a rare inflammatory skin disorder of unknown etiology first described by Wells in 1971 as "recurrent granulomatous dermatitis with eosinophilia" [<a href="#rid1">1</a>]. EC is characterized clinically by pruritic, erythematous plaques resembling infectious cellulitis and histologically by the presence of edema, infiltration of eosinophils, and "flame figures" in the dermis. The exact nature of EC remains controversial. Most authors considered EC to be a specific disorder with a unique constellation of clinical and histopathologic signs, although many of the clinical and histologic features of EC are not specific, as they can be found in other inflammatory disorders [<a href="#rid2">2,3</a>].</p><p>This topic will discuss the pathogenesis, clinical manifestations, diagnosis, and treatment of EC. Hypereosinophilic syndromes and other disease associated with eosinophilia are reviewed separately. Angiolymphoid hyperplasia with eosinophilia and Kimura disease are also discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2211.html" rel="external">"Hypereosinophilic syndromes: Clinical manifestations, pathophysiology, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/100544.html" rel="external">"Eosinophil biology and causes of eosinophilia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5691.html" rel="external">"Approach to the patient with unexplained eosinophilia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/90449.html" rel="external">"Angiolymphoid hyperplasia with eosinophilia and Kimura disease"</a>.)</p><p></p><p class="headingAnchor" id="H199211829"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The epidemiology of eosinophilic cellulitis (EC) is not well defined. The prevalence and incidence of EC are unknown. EC is thought to predominantly occur in adults, with peak incidence in the second and third decades of life [<a href="#rid4">4,5</a>]. However, EC occurs in patients of all ages, and a case of congenital EC has even been reported [<a href="#rid6">6</a>].</p><p>There is no sex predilection for EC in adults, but there may be a male predilection for EC in children [<a href="#rid7">7</a>]. There is no known racial or ethnic predilection for EC.</p><p class="headingAnchor" id="H634684988"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The pathogenesis of eosinophilic cellulitis (EC) is unclear. It appears to be a reaction pattern to a variety of stimuli, rather than a disease with a single etiology. Most of our understanding of the pathogenetic mechanisms underlying EC is derived from single case reports. Some have suggested that EC is caused by a delayed type (type IV) hypersensitivity reaction, similar to allergic contact dermatitis [<a href="#rid8">8,9</a>]. </p><p>A case report examined peripheral blood T cell receptor gamma gene rearrangements and found several clonal populations of circulating T cells; in addition, interleukin (IL)-5 expression was significantly increased in in vitro assays of the patient's peripheral blood mononuclear cells [<a href="#rid10">10</a>]. Another case report found elevated levels of peripheral CD4<sup>+</sup>CD7<sup>-</sup> cells expressing mRNA for IL-5, which decreased with successful treatment [<a href="#rid11">11</a>]. </p><p>Eosinophil degranulation leads to the release of eosinophil cationic and major basic proteins, which may have toxic effects on tissue and further activate other immune cells [<a href="#rid12">12-15</a>] (see  <a class="medical medical_review" href="/z/d/html/100544.html" rel="external">"Eosinophil biology and causes of eosinophilia"</a>). Elevated levels of IL-5 and eosinophil cationic protein in serum and fluid extracted from bullous lesions, which fluctuated and correlated with disease activity and recurrence, were described in one patient [<a href="#rid16">16</a>]. Eosinophilic major basic protein has been found surrounding collagen fibers using immunofluorescence and is thought to contribute to the formation of flame figures [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H484516837"><span class="h2">Eliciting factors</span><span class="headingEndMark"> — </span>A variety of different stimuli for EC have been proposed, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Infections:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Viral (varicella, mumps, parvovirus, coxsackievirus, coronavirus disease 2019 [COVID-19]) [<a href="#rid7">7,18-21</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Fungal (<em>Trichophyton rubrum</em>)</p><p class="bulletIndent2"><span class="glyph">•</span>Bacterial (<em>Mycoplasma</em>) [<a href="#rid22">22</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Parasitic infestations (giardiasis, toxocariasis, onchocerciasis) [<a href="#rid23">23,24</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Insect bite or sting (bees, ticks, fleas, spiders) [<a href="#rid7">7,25,26</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vaccines (hepatitis B; diphtheria, tetanus, and pertussis [DTaP]; tetanus; COVID-19) [<a href="#rid27">27-31</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drugs (<a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a>, <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>, <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">ustekinumab</a>, penicillins, <a class="drug drug_general" data-topicid="10113" href="/z/d/drug information/10113.html" rel="external">lincomycin</a>, <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a>, <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a>, <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a>, <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a>, <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a>, <a class="drug drug_general" data-topicid="9240" href="/z/d/drug information/9240.html" rel="external">chlorambucil</a>, anticholinergics, anesthetics, <a class="drug drug_general" data-topicid="9321" href="/z/d/drug information/9321.html" rel="external">danazol</a>, acetylsalicylic acid, <a class="drug drug_general" data-topicid="110865" href="/z/d/drug information/110865.html" rel="external">tenoxicam</a>, <a class="drug drug_general" data-topicid="9348" href="/z/d/drug information/9348.html" rel="external">diclofenac</a> sodium and <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">amoxicillin</a>, thiazides) [<a href="#rid3">3,10,32-36</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Delayed type (type IV) hypersensitivity (thimerosal in vaccines [<a href="#rid8">8,37</a>], aluminum in vaccines [<a href="#rid38">38</a>], paraphenylenediamine in a temporary tattoo [<a href="#rid9">9</a>])</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Malignancy (metastatic renal carcinoma [<a href="#rid39">39</a>], chronic lymphocytic leukemia [<a href="#rid40">40,41</a>])</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Atopic dermatitis [<a href="#rid42">42</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In utero exposure to medications [<a href="#rid6">6</a>]</p><p></p><p>Reactions may be delayed and have been reported to occur as long as 15 days after the exposure [<a href="#rid8">8</a>]. A case report of three family members with short stature and developmental delay suggested that EC may have an underlying genetic predisposition [<a href="#rid43">43</a>].</p><p>None of the above-mentioned triggers or mechanisms have been definitively proven. Many cases have been reported with no relevant prior exposures or etiologies [<a href="#rid33">33,34</a>].</p><p class="headingAnchor" id="H4005456867"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Eosinophilic cellulitis (EC) is characterized by the sudden onset of single or multiple pruritic, erythematous plaques, most often located on the extremities, that resemble infectious cellulitis (<a class="graphic graphic_picture graphicRef87394" href="/z/d/graphic/87394.html" rel="external">picture 1</a>). However, the clinical presentation may be heterogeneous, with morphologically different lesions coexisting in the same patient. In a review of 32 published cases of EC, all patients presented with large, erythematous plaques; in some, other types of lesions were also present, including vesicles (19 percent), bullae (34 percent), papules (22 percent), and nodules (16 percent) [<a href="#rid44">44</a>]. Seven clinical variants have been described: plaque-type, annular granuloma-like, urticaria-like, papulovesicular, bullous, papulonodular, and fixed drug eruption-like [<a href="#rid33">33</a>]. An erysipelas-like presentation of Wells syndrome has been reported [<a href="#rid45">45</a>].</p><p>Lesions typically develop over a two- to three-day period and resolve without scarring in two to eight weeks [<a href="#rid34">34</a>]. Lesions may be localized or diffuse and are most commonly located on the trunk and limbs, but can also occur on the face, eyelids, ears, scalp, axillae, and groin, and even involve the tongue and throat [<a href="#rid44">44</a>].</p><p>Itching and burning may precede or occur simultaneously with visible lesions. Lesions may be warm to touch, but generally are not tender and do not respond to antimicrobial therapy as in bacterial cellulitis [<a href="#rid44">44</a>].</p><p>Approximately one in five patients may present with systemic symptoms, including fever, malaise, and/or arthralgias [<a href="#rid44">44</a>]. The presence of systemic symptoms in EC may indicate a more severe or progressive course [<a href="#rid46">46</a>].</p><p>Laboratory abnormalities may include peripheral eosinophilia (50 to 67 percent), leukocytosis (41 percent), and elevated erythrocyte sedimentation rate, C-reactive protein, antinuclear antibodies, and serum immunoglobulin E (IgE) [<a href="#rid34">34,44,47,48</a>]. However, none of these findings are required for diagnosis.</p><p class="headingAnchor" id="H3228624311"><span class="h2">Clinical course and complications</span><span class="headingEndMark"> — </span>In most cases, lesions resolve in two to eight weeks without scarring [<a href="#rid49">49</a>]. However, in some patients the course may be prolonged, with lesions lasting for months or years. Lesions may recur in the same location, even after a complete and prolonged remission. </p><p>Superinfection with <em>Staphylococcus aureus</em>,<em> Pseudomonas aeruginosa</em>, and other bacteria may occur [<a href="#rid49">49,50</a>]. Atrophic scarring, scarring alopecia, and dyspigmentation have been reported in complicated cases [<a href="#rid49">49,50</a>]. </p><p class="headingAnchor" id="H1996760939"><span class="h1">PATHOLOGY</span><span class="headingEndMark"> — </span>Eosinophilic cellulitis (EC) is histologically characterized by the presence of edema, infiltration of eosinophils, and "flame figures" in the dermis in virtually all cases [<a href="#rid44">44</a>]. A superficial and deep, perivascular, chronic, inflammatory infiltrate may be present [<a href="#rid51">51</a>]. Flame figures are composed of eosinophil major basic protein surrounding collagen fibers [<a href="#rid17">17</a>]. Of note, they may be detected in other eosinophilic dermatoses associated with cutaneous eosinophilia, such as bullous pemphigoid, eczema, prurigo, pemphigoid gestationis, drug eruptions, and scabies [<a href="#rid2">2,52,53</a>]. </p><p>Some authors have described different stages of lesions, with dermal edema and infiltration of eosinophils occurring early on in lesions ("acute stage"), followed by later formation of flame figures ("subacute stage") [<a href="#rid54">54</a>]. As EC lesions resolve ("resolving stage"), there can be phagocytic histiocytes palisading around the flame figures, foreign-body giant cells, and granuloma formation [<a href="#rid54">54</a>]. Intense edema in the dermis and/or epidermis may result in bullae formation [<a href="#rid53">53,55</a>].</p><p>Vasculitis is absent [<a href="#rid32">32,51,54</a>]. Direct immunofluorescence and special stains for microorganisms are negative [<a href="#rid51">51,54</a>]. The stratum corneum is typically normal, though mild compact orthokeratosis or focal parakeratosis has been observed [<a href="#rid53">53</a>].</p><p class="headingAnchor" id="H2508627739"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of eosinophilic cellulitis (EC) is difficult and often delayed, as most patients are initially misdiagnosed with bacterial cellulitis and treated with antibiotic therapy. The diagnosis of EC should be suspected in patients with a clinical history of recurrent, pruritic, cellulitic plaques that are nontender and do not respond to antibiotic treatment. (See  <a class="medical medical_review" href="/z/d/html/110529.html" rel="external">"Cellulitis and skin abscess: Epidemiology, microbiology, clinical manifestations, and diagnosis"</a>.)</p><p>A skin biopsy showing characteristic histopathologic findings (eosinophilic dermal infiltrate, "flame figures," and a blood cell count demonstrating peripheral eosinophilia) support the clinical diagnosis. However, as the clinical, histologic, and laboratory findings of EC are not specific, a careful clinicopathologic correlation is necessary for the definitive diagnosis. </p><p>Additional diagnostic workup may be needed to identify potential triggers and rule out other disorders that share similar features [<a href="#rid32">32</a>]. (See <a class="local">'Eliciting factors'</a> above and <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H1275587107"><span class="h2">Skin biopsy</span><span class="headingEndMark"> — </span>A punch biopsy with standard hematoxylin and eosin staining is typically adequate for identification of the characteristic histologic findings of EC. (See <a class="local">'Pathology'</a> above.)</p><p>Immunohistochemistry and special stains are generally not required for the diagnosis of EC. However, in resolving lesions with phagocytic palisading histiocytes, special stains for microorganisms and tissue culture may be required to rule out deep fungal or mycobacterial infections [<a href="#rid51">51</a>]. Direct and/or indirect immunofluorescence may be performed to rule out bullous pemphigoid. </p><p class="headingAnchor" id="H3034211387"><span class="h2">Laboratory tests and imaging</span><span class="headingEndMark"> — </span>A complete blood cell count with differential should be performed to detect peripheral eosinophilia. Additional testing (eg, skin bacterial cultures, potassium hydroxide [KOH] preparation, stool examination for parasites, serologic testing) may be needed to exclude other conditions with or without associated eosinophilia that may mimic EC. (See <a class="local">'Differential diagnosis'</a> below.)</p><p>Occasionally, magnetic resonance imaging (MRI) has been used to rule out osteomyelitis, computed tomography (CT) scan to rule out an underlying abscess, as well as magnetic resonance venography or venous Doppler examination to rule out deep vein thrombosis [<a href="#rid51">51</a>].</p><p class="headingAnchor" id="H161280397"><span class="h2">Proposed diagnostic criteria</span><span class="headingEndMark"> — </span>A series of clinical and pathologic criteria have been proposed to help in the diagnosis of EC [<a href="#rid3">3</a>]. However, they have not been validated in large series of patients:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Major</strong> <strong>criteria</strong> (two of four are required):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Clinical presentation consistent with EC:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Plaque-type</p><p class="bulletIndent3"><span class="glyph">-</span>Annular granuloma-like</p><p class="bulletIndent3"><span class="glyph">-</span>Urticaria-like</p><p class="bulletIndent3"><span class="glyph">-</span>Papulovesicular</p><p class="bulletIndent3"><span class="glyph">-</span>Bullous</p><p class="bulletIndent3"><span class="glyph">-</span>Papulonodular</p><p class="bulletIndent3"><span class="glyph">-</span>Fixed drug eruption-like</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Relapsing, remitting course</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>No evidence of systemic disease</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Histologic features of dermal eosinophilic infiltration and no vasculitis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Minor criteria </strong>(at least one is required):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Flame figures</p><p class="bulletIndent2"><span class="glyph">•</span>Histologic features of granulomatous change</p><p class="bulletIndent2"><span class="glyph">•</span>Peripheral eosinophilia, not persistent and not &gt;1500/microL</p><p class="bulletIndent2"><span class="glyph">•</span>Triggering factor (eg, drug)</p><p></p><p class="headingAnchor" id="H3954029370"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>A wide range of disorders present with clinical and/or histopathologic findings that overlap with those of eosinophilic cellulitis (EC); most, but not all, of them are associated with peripheral eosinophilia [<a href="#rid2">2,18,44,56</a>] (see  <a class="medical medical_review" href="/z/d/html/100544.html" rel="external">"Eosinophil biology and causes of eosinophilia"</a>). These include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infections and infestations</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bacterial cellulitis </strong>– Bacterial cellulitis presents with erythema, edema, and warmth of well-demarcated skin areas, usually associated with systemic symptoms, including fever, chills, and malaise. Lesions are most often located on the lower extremities and are typically unilateral (<a class="graphic graphic_picture graphicRef82542" href="/z/d/graphic/82542.html" rel="external">picture 2</a>). An elevated white blood cell count with neutrophilia supports the diagnosis. On histology, there is dermal edema and a nonspecific neutrophilic and lymphocytic infiltrate. (See  <a class="medical medical_review" href="/z/d/html/110529.html" rel="external">"Cellulitis and skin abscess: Epidemiology, microbiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Tinea corporis</strong> – Tinea corporis is a dermatophytic infection that usually presents with pruritic, circular or oval, erythematous, scaling patch or plaque that spreads centrifugally (<a class="graphic graphic_picture graphicRef103984 graphicRef53823 graphicRef75928" href="/z/d/graphic/103984.html" rel="external">picture 3A-C</a>). A potassium hydroxide (KOH) preparation will show the segmented hyphae characteristic of dermatophyte infections (<a class="graphic graphic_picture graphicRef100246" href="/z/d/graphic/100246.html" rel="external">picture 4</a>). (See  <a class="medical medical_review" href="/z/d/html/4030.html" rel="external">"Dermatophyte (tinea) infections"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Toxocariasis </strong>– Toxocariasis (visceral larva migrans) is an infestation with the larvae of the dog ascarid <em>Toxocara canis</em>. Heavy infestation may present with fever, anorexia, malaise, hepatomegaly, and a pruritic, urticaria-like cutaneous eruption. The diagnosis can be confirmed by enzyme-linked immunosorbent assay (ELISA) demonstrating immunoglobulin G (IgG) antibodies to <em>Toxocara</em> antigens. (See  <a class="medical medical_review" href="/z/d/html/5716.html" rel="external">"Toxocariasis: Visceral and ocular larva migrans"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Scabies</strong> – Scabies presents with an intensely pruritic eruption of multiple small, erythematous papules, which are often excoriated (<a class="graphic graphic_picture graphicRef114532" href="/z/d/graphic/114532.html" rel="external">picture 5</a>); severe infestation may cause peripheral blood eosinophilia. The diagnosis is based on clinical history, physical examination, and demonstration of scabies mites in skin scrapings. In difficult cases, a skin biopsy may be needed. (See  <a class="medical medical_review" href="/z/d/html/4038.html" rel="external">"Scabies: Epidemiology, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Erythema migrans (EM)</strong> – EM is the most common manifestation of <em>Borrelia burgdorferi</em> infection (early localized Lyme disease). It presents as an erythematous plaque at the site of the tick bite that typically expands slowly over the course of days or weeks, often with central clearing (<a class="graphic graphic_picture graphicRef118894" href="/z/d/graphic/118894.html" rel="external">picture 6</a> and <a class="graphic graphic_picture graphicRef81270" href="/z/d/graphic/81270.html" rel="external">picture 7</a>). As EM appears before the development of an immune response, the diagnosis of early Lyme disease is clinical in a patient who lives in or has recently traveled to an area that is endemic for Lyme disease. (See  <a class="medical medical_review" href="/z/d/html/7913.html" rel="external">"Clinical manifestations of Lyme disease in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7914.html" rel="external">"Diagnosis of Lyme disease"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Arthropod bites</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Large local reaction to insect bites</strong> − Hypersensitivity reactions to mosquito and other insects bites present with itchy, red, warm swellings sometimes accompanied by low-grade fever and malaise. Clues to the diagnosis include a history of exposure to insect bites and the rapid development of lesions, typically within hours of the exposure. (See  <a class="medical medical_review" href="/z/d/html/16198.html" rel="external">"Allergic reactions to mosquito bites"</a> and  <a class="medical medical_review" href="/z/d/html/4088.html" rel="external">"Insect and other arthropod bites"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autoimmune dermatoses</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bullous pemphigoid (BP)</strong> – The prodromal phase of BP is characterized by pruritic, inflammatory plaques that may resemble EC (<a class="graphic graphic_picture graphicRef80385" href="/z/d/graphic/80385.html" rel="external">picture 8</a>). In this phase, histology shows eosinophilic spongiosis with a superficial dermal infiltrate of lymphocytes, eosinophils, and neutrophils. Direct immunofluorescence on a biopsy sample taken from the perilesional skin shows an IgG and/or C3 linear staining along the basement membrane zone. The diagnosis of BP is further confirmed by ELISA for antibodies to the BP antigen BP180 NC16A domain. (See  <a class="medical medical_review" href="/z/d/html/16176.html" rel="external">"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pemphigoid gestationis</strong> − Pemphigoid gestationis (formerly called herpes gestationis) is a rare autoimmune bullous disease that occurs during the second or third trimester of pregnancy. It presents with intensely pruritic plaques typically located on the abdomen (<a class="graphic graphic_picture graphicRef63947" href="/z/d/graphic/63947.html" rel="external">picture 9</a>). The diagnosis is confirmed by direct immunofluorescence on a biopsy of perilesional skin showing a linear deposit of IgG and/or C3 at the basement membrane zone and detection of circulating antibodies to BP180. (See  <a class="medical medical_review" href="/z/d/html/5564.html" rel="external">"Dermatoses of pregnancy", section on 'Pemphigoid gestationis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug reactions</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Maculopapular drug eruptions</strong> – Maculopapular (morbilliform) drug eruptions are characterized by erythematous macules and papules that predominantly involve the trunk and proximal extremities occurring 5 to 14 days after drug exposure (<a class="graphic graphic_picture graphicRef86509 graphicRef86552" href="/z/d/graphic/86509.html" rel="external">picture 10A-B</a>). Symptoms include pruritus, low-grade fever, and mild eosinophilia. Histologically, there is a superficial perivascular and interstitial infiltrate of lymphocytes, neutrophils, and eosinophils. The rapid resolution of the rash after drug discontinuation supports the diagnosis. (See  <a class="medical medical_review" href="/z/d/html/15762.html" rel="external">"Exanthematous (maculopapular) drug eruption"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Drug reaction with eosinophilia and systemic symptoms (DRESS)</strong> – DRESS is a potentially life-threatening, systemic hypersensitivity reaction characterized by fever; malaise; lymphadenopathy; maculopapular, confluent skin eruption (<a class="graphic graphic_picture graphicRef86763 graphicRef86860" href="/z/d/graphic/86763.html" rel="external">picture 11A-B</a>); variable organ involvement; and leukocytosis with eosinophilia and/or atypical lymphocytosis. The diagnosis is based upon the combination of clinical and laboratory findings and a history of exposure to drugs frequently associated to DRESS (<a class="graphic graphic_table graphicRef86760" href="/z/d/graphic/86760.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/16420.html" rel="external">"Drug reaction with eosinophilia and systemic symptoms (DRESS)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypereosinophilic syndromes</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Episodic angioedema with eosinophilia</strong> − Episodic angioedema with eosinophilia (Gleich syndrome) is a rare disorder characterized by recurrent episodes of angioedema, urticaria, pruritus, fever, weight gain, elevated serum immunoglobulin M (IgM) levels, and marked eosinophilia that occur at three to four week intervals and resolve spontaneously [<a href="#rid57">57,58</a>]. (See  <a class="medical medical_review" href="/z/d/html/2211.html" rel="external">"Hypereosinophilic syndromes: Clinical manifestations, pathophysiology, and diagnosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Eosinophilic granulomatosis with polyangiitis (EGPA)</strong> − EGPA, formerly called Churg-Strauss syndrome, is a rare, systemic vasculitis characterized by chronic rhinosinusitis, asthma, and marked peripheral blood eosinophilia. Cutaneous manifestations of EGPA include palpable purpura, infiltrated nodules and papules, livedo reticularis, necrotizing livedo, and migratory erythema (<a class="graphic graphic_picture graphicRef52628" href="/z/d/graphic/52628.html" rel="external">picture 12</a>). (See  <a class="medical medical_review" href="/z/d/html/4347.html" rel="external">"Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Eosinophilic fasciitis</strong> − Eosinophilic fasciitis, also called Shulman syndrome, is a rare disorder characterized in its early phase by symmetric limb or trunk erythema and edema that progresses to fibrosis, induration, and a peau d'orange appearance [<a href="#rid59">59</a>]. Peripheral eosinophilia is present in most patients. A deep skin biopsy down to the fascia and muscle surface shows edema of the subcutis and fascia with an infiltrate of lymphocytes, plasma cells, histiocytes, and eosinophils. (See  <a class="medical medical_review" href="/z/d/html/7547.html" rel="external">"Eosinophilic fasciitis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inflammatory and allergic dermatoses </strong><em>–</em><strong> </strong>A number of inflammatory and allergic dermatoses may share histopathologic and clinical features with EC. These include atopic dermatitis, allergic contact dermatitis, urticarial dermatitis, prurigo nodularis, and granuloma annulare. (See  <a class="medical medical_review" href="/z/d/html/1729.html" rel="external">"Atopic dermatitis (eczema): Pathogenesis, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/13655.html" rel="external">"Clinical features and diagnosis of allergic contact dermatitis"</a> and  <a class="medical medical_review" href="/z/d/html/96466.html" rel="external">"Urticarial dermatitis"</a> and  <a class="medical medical_review" href="/z/d/html/13667.html" rel="external">"Prurigo nodularis"</a> and  <a class="medical medical_review" href="/z/d/html/13705.html" rel="external">"Granuloma annulare: Epidemiology, clinical manifestations, and diagnosis"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eosinophilic dermatosis of hematologic malignancy </strong>– Eosinophilic dermatosis of hematologic malignancy (EDHM) is a rare condition characterized by itchy and sometimes painful papules and plaques resembling exaggerated insect bite reactions that occurs in patients with chronic lymphocytic leukemia or, less frequently, B cell non-Hodgkin lymphoma, acute lymphoblastic leukemia, acute monocytic leukemia, or large cell lymphoma [<a href="#rid60">60-62</a>]. EDHM lesions are predominately located on the limbs, but frequently occur on the trunk, and may be widespread. Histologically, there is a perivascular lymphohistiocytic and eosinophilic infiltrate in the papillary and mid-dermis that, in some cases, may extend to the reticular dermis and subcutaneous fat [<a href="#rid62">62</a>]. Overexpression of T helper type 2 (Th2) cell markers has been noted on immunohistochemistry [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mastocytoma</strong> – Cutaneous mastocytosis may present in children with reddish or skin-colored nodules or plaques that are in most cases solitary (<a class="graphic graphic_picture graphicRef50284 graphicRef76891" href="/z/d/graphic/50284.html" rel="external">picture 13A-B</a>). If rubbed, these lesions develop an urticarial reaction (Darier sign) that is pathognomonic. There is usually an associated mild peripheral eosinophilia. A skin biopsy can confirm the diagnosis. (See  <a class="medical medical_review" href="/z/d/html/103161.html" rel="external">"Mastocytosis (cutaneous and systemic) in children: Epidemiology, clinical manifestations, evaluation, and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H1072855755"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>There is no consensus regarding the optimal management of eosinophilic cellulitis (EC). No randomized controlled trials or large prospective studies of treatments in EC have been performed, and the available evidence is mainly derived from case reports and small case series [<a href="#rid44">44,64</a>].</p><p>Medium- to high-potency topical corticosteroids are the first-line therapy in patients with localized disease and especially in children [<a href="#rid8">8,44</a>]. Topical corticosteroids are applied twice daily until improvement. </p><p>Patients with generalized disease and those with localized disease that is not controlled with topical corticosteroids require a short course of systemic corticosteroids [<a href="#rid44">44,51</a>]. <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">Prednisolone</a> 0.5 to 1 mg/kg per day may be given for five to seven days and then tapered off over two to three weeks. </p><p>Alternative regimens that have been reported as effective include initial higher doses of oral corticosteroids (up to 2 mg/kg per day) [<a href="#rid51">51</a>], intravenous corticosteroids [<a href="#rid47">47</a>], and long courses of low-dose (5 mg every other day) oral corticosteroids [<a href="#rid65">65</a>]. If signs and symptoms recur upon discontinuation, alternative nonsteroidal therapies should be considered for long-term use. </p><p>Antihistamines may be an adjunctive therapy for control of pruritus but have no effect on the skin lesions [<a href="#rid44">44,66</a>]. Other therapies that have been used in recurrent or refractory cases include <a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">mepolizumab</a> [<a href="#rid67">67-69</a>], <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">omalizumab</a> [<a href="#rid70">70</a>], <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">dupilumab</a> [<a href="#rid71">71</a>], <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> [<a href="#rid72">72</a>], <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a> [<a href="#rid73">73</a>], <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> [<a href="#rid54">54</a>], <a class="drug drug_general" data-topicid="8502" href="/z/d/drug information/8502.html" rel="external">griseofulvin</a> [<a href="#rid74">74</a>], <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> [<a href="#rid75">75</a>], <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> [<a href="#rid76">76</a>], interferon alpha [<a href="#rid77">77</a>], and psoralen with ultraviolet A (PUVA) phototherapy [<a href="#rid78">78</a>]. </p><p class="headingAnchor" id="H2078624418"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>The overall prognosis of eosinophilic cellulitis (EC) is good. Lesions may spontaneously improve or improve with treatment of any underlying disorders [<a href="#rid32">32</a>]. However, recurrence is common in both adults and children, particularly among persons with multiple body areas involved and spreading of lesions beyond the area of initial involvement [<a href="#rid8">8,44,54</a>]. Multiple recurrences have been reported, with a mean number of four relapses in adults and three in children over many years [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H663439581"><span class="h1">FOLLOW-UP</span><span class="headingEndMark"> — </span>Clinical follow-up is indicated for all patients with eosinophilic cellulitis (EC) to assess the response to treatment and disease recurrence. Surveillance for the development of hematologic malignancy is indicated particularly for patients with chronic comorbidities or presenting with systemic symptoms [<a href="#rid60">60</a>]. </p><p class="headingAnchor" id="H415519202"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and pathogenesis </strong>– Eosinophilic cellulitis (EC) is a rare inflammatory skin disorder characterized clinically by pruritic, erythematous plaques and/or vesicobullae resembling infectious cellulitis and histologically by the presence of edema, infiltration of eosinophils, and "flame figures" in the dermis. EC appears to be a reaction pattern to a variety of stimuli rather than a disease with a single etiology. Proposed trigger factors include infections, parasitic infestations, insect bites, vaccines, delayed type sensitizers, drugs, and malignancy. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation </strong>– EC presents with the sudden onset of single or multiple erythematous plaques most often located on the extremities (<a class="graphic graphic_picture graphicRef87394" href="/z/d/graphic/87394.html" rel="external">picture 1</a>). Lesions resemble bacterial cellulitis, but are nontender and do not respond to antimicrobial therapy. In most cases, lesions resolve in two to eight weeks without scarring. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>– The diagnosis of EC should be suspected in patients with a clinical history of recurrent, pruritic, erythematous plaques resembling bacterial cellulitis that do not respond to antibiotic treatment. A skin biopsy showing characteristic histopathologic findings (eosinophilic dermal infiltrate, "flame figures," and a blood cell count demonstrating peripheral eosinophilia) supports the clinical diagnosis. (See <a class="local">'Diagnosis'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis </strong>– The differential diagnosis of EC is broad and includes infections and infestations, insect bites, drug reactions, bullous pemphigoid, hypereosinophilic syndromes with cutaneous manifestations, inflammatory and allergic dermatoses, and eosinophilic dermatosis associated with hematologic malignancy. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management </strong>– Medium- to high-potency topical corticosteroids are the first-line therapy for patients with localized disease and children with EC. Patients with extensive disease typically respond to a short course of oral corticosteroids. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis </strong>– The overall prognosis of EC is favorable. However, patients may experience multiple relapses over months or years. (See <a class="local">'Prognosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Wells GC. Recurrent granulomatous dermatitis with eosinophilia. Trans St Johns Hosp Dermatol Soc 1971; 57:46.</a></li><li><a class="nounderline abstract_t">Aberer W, Konrad K, Wolff K. Wells' syndrome is a distinctive disease entity and not a histologic diagnosis. J Am Acad Dermatol 1988; 18:105.</a></li><li><a class="nounderline abstract_t">Heelan K, Ryan JF, Shear NH, Egan CA. Wells syndrome (eosinophilic cellulitis): Proposed diagnostic criteria and a literature review of the drug-induced variant. J Dermatol Case Rep 2013; 7:113.</a></li><li><a class="nounderline abstract_t">Chan JK, Hui PK, Ng CS, et al. Epithelioid haemangioma (angiolymphoid hyperplasia with eosinophilia) and Kimura's disease in Chinese. Histopathology 1989; 15:557.</a></li><li><a class="nounderline abstract_t">Hui PK, Chan JK, Ng CS, et al. Lymphadenopathy of Kimura's disease. Am J Surg Pathol 1989; 13:177.</a></li><li><a class="nounderline abstract_t">Garty BZ, Feinmesser M, David M, et al. Congenital Wells syndrome. Pediatr Dermatol 1997; 14:312.</a></li><li><a class="nounderline abstract_t">Reichel M, Isseroff RR, Vogt PJ, Gandour-Edwards R. Wells' syndrome in children: varicella infection as a precipitating event. Br J Dermatol 1991; 124:187.</a></li><li><a class="nounderline abstract_t">Koh KJ, Warren L, Moore L, et al. Wells' syndrome following thiomersal-containing vaccinations. Australas J Dermatol 2003; 44:199.</a></li><li><a class="nounderline abstract_t">Nacaroglu HT, Celegen M, Karkıner CS, et al. Eosinophilic cellulitis (Wells' syndrome) caused by a temporary henna tattoo. Postepy Dermatol Alergol 2014; 31:322.</a></li><li><a class="nounderline abstract_t">French LE, Shapiro M, Junkins-Hopkins JM, et al. Eosinophilic fasciitis and eosinophilic cellulitis in a patient with abnormal circulating clonal T cells: increased production of interleukin 5 and inhibition by interferon alfa. J Am Acad Dermatol 2003; 49:1170.</a></li><li><a class="nounderline abstract_t">Yagi H, Tokura Y, Matsushita K, et al. Wells' syndrome: a pathogenic role for circulating CD4+CD7- T cells expressing interleukin-5 mRNA. Br J Dermatol 1997; 136:918.</a></li><li><a class="nounderline abstract_t">Rothenberg ME, Hogan SP. The eosinophil. Annu Rev Immunol 2006; 24:147.</a></li><li><a class="nounderline abstract_t">Slifman NR, Loegering DA, McKean DJ, Gleich GJ. Ribonuclease activity associated with human eosinophil-derived neurotoxin and eosinophil cationic protein. J Immunol 1986; 137:2913.</a></li><li><a class="nounderline abstract_t">Gleich GJ, Adolphson CR. The eosinophilic leukocyte: structure and function. Adv Immunol 1986; 39:177.</a></li><li><a class="nounderline abstract_t">Zheutlin LM, Ackerman SJ, Gleich GJ, Thomas LL. Stimulation of basophil and rat mast cell histamine release by eosinophil granule-derived cationic proteins. J Immunol 1984; 133:2180.</a></li><li><a class="nounderline abstract_t">España A, Sanz ML, Sola J, Gil P. Wells' syndrome (eosinophilic cellulitis): correlation between clinical activity, eosinophil levels, eosinophil cation protein and interleukin-5. Br J Dermatol 1999; 140:127.</a></li><li><a class="nounderline abstract_t">Peters MS, Schroeter AL, Gleich GJ. Immunofluorescence identification of eosinophil granule major basic protein in the flame figures of Wells' syndrome. Br J Dermatol 1983; 109:141.</a></li><li><a class="nounderline abstract_t">Wells GC, Smith NP. Eosinophilic cellulitis. Br J Dermatol 1979; 100:101.</a></li><li><a class="nounderline abstract_t">Cherng E, McClung AA, Rosenthal HM, et al. Wells' syndrome associated with parvovirus in a 5-year old boy. Pediatr Dermatol 2012; 29:762.</a></li><li><a class="nounderline abstract_t">Yoshii Y, Ishikawa T, Munetsugu T, et al. Wells' Syndrome Associated with Coxsackievirus A6 Infection. Acta Derm Venereol 2018; 98:791.</a></li><li><a class="nounderline abstract_t">Moseley I, Yang EJ, Mathieu RJ, et al. Wells syndrome as a presenting sign of COVID-19 in the setting of allergic rhinitis and iron deficiency anemia. JAAD Case Rep 2022; 23:27.</a></li><li><a class="nounderline abstract_t">Kim SH, Yoo HW, Kim YM, Kim HY. Wells' syndrome related to Mycoplasma pneumoniae in a 5-year-old boy. Pediatr Int 2020; 62:635.</a></li><li><a class="nounderline abstract_t">Canonne D, Dubost-Brama A, Segard M, et al. Wells' syndrome associated with recurrent giardiasis. Br J Dermatol 2000; 143:425.</a></li><li><a class="nounderline abstract_t">Bassukas ID, Gaitanis G, Zioga A, et al. Febrile "migrating" eosinophilic cellulitis with hepatosplenomegaly: adult toxocariasis - a case report. Cases J 2008; 1:356.</a></li><li><a class="nounderline abstract_t">Melski JW. Wells' syndrome, insect bites, and eosinophils. Dermatol Clin 1990; 8:287.</a></li><li><a class="nounderline abstract_t">Schorr WF, Tauscheck AL, Dickson KB, Melski JW. Eosinophilic cellulitis (Wells' syndrome): histologic and clinical features in arthropod bite reactions. J Am Acad Dermatol 1984; 11:1043.</a></li><li><a class="nounderline abstract_t">Calvert J, Shors AR, Hornung RL, et al. Relapse of Wells' syndrome in a child after tetanus-diphtheria immunization. J Am Acad Dermatol 2006; 54:S232.</a></li><li><a class="nounderline abstract_t">Moreno M, Luelmo J, Monteagudo M, et al. Wells' syndrome related to tetanus vaccine. Int J Dermatol 1997; 36:524.</a></li><li><a class="nounderline abstract_t">Yu AM, Ito S, Leibson T, et al. Pediatric Wells syndrome (eosinophilic cellulitis) after vaccination: A case report and review of the literature. Pediatr Dermatol 2018; 35:e262.</a></li><li><a class="nounderline abstract_t">Ikediobi O, Eichenfield DZ, Barrio VR. Eosinophilic cellulitis in response to BNT162b2 COVID-19 vaccination. Pediatr Dermatol 2022; 39:823.</a></li><li><a class="nounderline abstract_t">de Montjoye L, Marot L, Baeck M. Eosinophilic cellulitis after BNT162b2 mRNA Covid-19 vaccine. J Eur Acad Dermatol Venereol 2022; 36:e26.</a></li><li><a class="nounderline abstract_t">Gilliam AE, Bruckner AL, Howard RM, et al. Bullous "cellulitis" with eosinophilia: case report and review of Wells' syndrome in childhood. Pediatrics 2005; 116:e149.</a></li><li><a class="nounderline abstract_t">Caputo R, Marzano AV, Vezzoli P, Lunardon L. Wells syndrome in adults and children: a report of 19 cases. Arch Dermatol 2006; 142:1157.</a></li><li><a class="nounderline abstract_t">Green WH, Yosipovitch G, Pichardo RO. Recurrent, pruritic dermal plaques and bullae. Diagnosis: eosinophilic cellulitis (Wells syndrome). Arch Dermatol 2007; 143:791.</a></li><li><a class="nounderline abstract_t">Tugnet N, Youssef A, Whallett AJ. Wells' syndrome (eosinophilic cellulitis) secondary to infliximab. Rheumatology (Oxford) 2012; 51:195.</a></li><li><a class="nounderline abstract_t">Rozenblat M, Cohen-Barak E, Dodiuk-Gad R, Ziv M. Wells' Syndrome Induced by Ustekinumab. Isr Med Assoc J 2019; 21:65.</a></li><li><a class="nounderline abstract_t">Safran T, Masckauchan M, Maj J, Green L. Wells syndrome secondary to influenza vaccination: A case report and review of the literature. Hum Vaccin Immunother 2018; 14:958.</a></li><li><a class="nounderline abstract_t">Fournier C, Auger I, Houle MC. Wells syndrome (eosinophilic cellulitis) following vaccination: Two pediatric cases with positive patch test to aluminium salts. Contact Dermatitis 2020; 82:401.</a></li><li><a class="nounderline abstract_t">Rajpara A, Liolios A, Fraga G, Blackmon J. Recurrent paraneoplastic wells syndrome in a patient with metastatic renal cell cancer. Dermatol Online J 2014; 20.</a></li><li><a class="nounderline abstract_t">Omigawa C, Namiki T, Ueno M, et al. Case of Wells' syndrome: A rare association with the clinical course of chronic lymphocytic leukemia. J Dermatol 2019; 46:e57.</a></li><li><a class="nounderline abstract_t">Qiao J, Sun CE, Zhu W, et al. Flame figures associated with eosinophilic dermatosis of hematologic malignancy: is it possible to distinguish the condition from eosinophilic cellulitis in patients with hematoproliferative disease? Int J Clin Exp Pathol 2013; 6:1683.</a></li><li><a class="nounderline abstract_t">Brun J, Chiaverini C, Bessis D, et al. [Wells Syndrome in children and atopy: Retrospective study of 11 cases and review of the literature]. Ann Dermatol Venereol 2015; 142:320.</a></li><li><a class="nounderline abstract_t">Davis MD, Brown AC, Blackston RD, et al. Familial eosinophilic cellulitis, dysmorphic habitus, and mental retardation. J Am Acad Dermatol 1998; 38:919.</a></li><li><a class="nounderline abstract_t">Sinno H, Lacroix JP, Lee J, et al. Diagnosis and management of eosinophilic cellulitis (Wells' syndrome): A case series and literature review. Can J Plast Surg 2012; 20:91.</a></li><li><a class="nounderline abstract_t">Belfeki N, Gharbi E, Flateau C, Diamantis S. Erysipelas-like presentation of Wells' syndrome (eosinophilic cellulitis). Reumatismo 2020; 71:226.</a></li><li><a class="nounderline abstract_t">Kamani N, Lipsitz PJ. Eosinophilic cellulitis in a family. Pediatr Dermatol 1987; 4:220.</a></li><li><a class="nounderline abstract_t">Carlesimo M, Fidanza L, Mari E, et al. Wells Syndrome with Multiorgan Involvement Mimicking Hypereosinophilic Syndrome. Case Rep Dermatol 2009; 1:44.</a></li><li><a class="nounderline abstract_t">Shodo M, Mizuhashi K, Kimura T. [A case of eosinophilic cellulitis (Wells' syndrome)]. Arerugi 2004; 53:1079.</a></li><li><a class="nounderline abstract_t">Anderson CR, Jenkins D, Tron V, Prendiville JS. Wells' syndrome in childhood: case report and review of the literature. J Am Acad Dermatol 1995; 33:857.</a></li><li><a class="nounderline abstract_t">Nielsen T, Schmidt H, Søgaard H. Eosinophilic cellulitis. (Well's syndrome) in a child. Arch Dermatol 1981; 117:427.</a></li><li><a class="nounderline abstract_t">Gandhi RK, Coloe J, Peters S, et al. Wells syndrome (eosinophilic cellulitis): a clinical imitator of bacterial cellulitis. J Clin Aesthet Dermatol 2011; 4:55.</a></li><li><a class="nounderline abstract_t">Rossini MS, de Souza EM, Cintra ML, et al. Cutaneous adverse reaction to 2-chlorodeoxyadenosine with histological flame figures in patients with chronic lymphocytic leukaemia. J Eur Acad Dermatol Venereol 2004; 18:538.</a></li><li><a class="nounderline abstract_t">Wood C, Miller AC, Jacobs A, et al. Eosinophilic infiltration with flame figures. A distinctive tissue reaction seen in Wells' syndrome and other diseases. Am J Dermatopathol 1986; 8:186.</a></li><li><a class="nounderline abstract_t">Moossavi M, Mehregan DR. Wells' syndrome: a clinical and histopathologic review of seven cases. Int J Dermatol 2003; 42:62.</a></li><li><a class="nounderline abstract_t">Brehmer-Andersson E, Kaaman T, Skog E, Frithz A. The histopathogenesis of the flame figure in Wells' syndrome based on five cases. Acta Derm Venereol 1986; 66:213.</a></li><li><a class="nounderline abstract_t">Falagas ME, Vergidis PI. Narrative review: diseases that masquerade as infectious cellulitis. Ann Intern Med 2005; 142:47.</a></li><li><a class="nounderline abstract_t">Gleich GJ, Schroeter AL, Marcoux JP, et al. Episodic angioedema associated with eosinophilia. N Engl J Med 1984; 310:1621.</a></li><li><a class="nounderline abstract_t">Khoury P, Herold J, Alpaugh A, et al. Episodic angioedema with eosinophilia (Gleich syndrome) is a multilineage cell cycling disorder. Haematologica 2015; 100:300.</a></li><li><a class="nounderline abstract_t">Mazori DR, Femia AN, Vleugels RA. Eosinophilic Fasciitis: an Updated Review on Diagnosis and Treatment. Curr Rheumatol Rep 2017; 19:74.</a></li><li><a class="nounderline abstract_t">Barzilai A, Shpiro D, Goldberg I, et al. Insect bite-like reaction in patients with hematologic malignant neoplasms. Arch Dermatol 1999; 135:1503.</a></li><li><a class="nounderline abstract_t">Farber MJ, La Forgia S, Sahu J, Lee JB. Eosinophilic dermatosis of hematologic malignancy. J Cutan Pathol 2012; 39:690.</a></li><li><a class="nounderline abstract_t">Grandi V, Maglie R, Antiga E, et al. Eosinophilic dermatosis of hematologic malignancy: A retrospective cohort of 37 patients from an Italian center. J Am Acad Dermatol 2019; 81:246.</a></li><li><a class="nounderline abstract_t">Maglie R, Ugolini F, De Logu F, et al. Overexpression of helper T cell type 2-related molecules in the skin of patients with eosinophilic dermatosis of hematologic malignancy. J Am Acad Dermatol 2022; 87:761.</a></li><li><a class="nounderline abstract_t">Räßler F, Lukács J, Elsner P. Treatment of eosinophilic cellulitis (Wells syndrome) - a systematic review. J Eur Acad Dermatol Venereol 2016; 30:1465.</a></li><li><a class="nounderline abstract_t">Coldiron BM, Robinson JK. Low-dose alternate-day prednisone for persistent Wells' syndrome. Arch Dermatol 1989; 125:1625.</a></li><li><a class="nounderline abstract_t">Aroni K, Aivaliotis M, Liossi A, Davaris P. Eosinophilic cellulitis in a child successfully treated with cetirizine. Acta Derm Venereol 1999; 79:332.</a></li><li><a class="nounderline abstract_t">Terhorst-Molawi D, Altrichter S, Röwert J, et al. Effective treatment with mepolizumab in a patient with refractory Wells syndrome. J Dtsch Dermatol Ges 2020; 18:737.</a></li><li><a class="nounderline abstract_t">Żychowska M, Tutka K, Reich A. Mepolizumab Therapy for Recalcitrant Eosinophilic Annular Erythema in an Adult: A Case Report and Review of Treatment Options. Dermatol Ther (Heidelb) 2020; 10:893.</a></li><li><a class="nounderline abstract_t">Herout S, Bauer WM, Schuster C, Stingl G. Eosinophilic cellulitis (Wells syndrome) successfully treated with mepolizumab. JAAD Case Rep 2018; 4:548.</a></li><li><a class="nounderline abstract_t">Coattrenec Y, Ibrahim Yasmine L, Harr T, et al. Long-term Remission of Wells Syndrome With Omalizumab. J Investig Allergol Clin Immunol 2020; 30:58.</a></li><li><a class="nounderline abstract_t">Traidl S, Angela Y, Kapp A, et al. Dupilumab in eosinophilic cellulitis (Wells' syndrome) - case report of a potential new treatment option. J Dtsch Dermatol Ges 2021; 19:1653.</a></li><li><a class="nounderline abstract_t">Herr H, Koh JK. Eosinophilic cellulitis (Wells' syndrome) successfully treated with low-dose cyclosporine. J Korean Med Sci 2001; 16:664.</a></li><li><a class="nounderline abstract_t">Marks R. Eosinophilic cellulitis--a response to treatment with dapsone: case report. Australas J Dermatol 1980; 21:10.</a></li><li><a class="nounderline abstract_t">Sharma PK, Gautam RK, Sharma AK. Eosinophilic cellulitis - A case study and management with griseofulvin. Indian J Dermatol Venereol Leprol 1995; 61:163.</a></li><li><a class="nounderline abstract_t">Stam-Westerveld EB, Daenen S, Van der Meer JB, Jonkman MF. Eosinophilic cellulitis (Wells' syndrome): treatment with minocycline. Acta Derm Venereol 1998; 78:157.</a></li><li><a class="nounderline abstract_t">Paquet P, Laso-Dosal F, de la Brassinne M. Wells' syndrome: report of 2 cases. Dermatology 1992; 184:139.</a></li><li><a class="nounderline abstract_t">Husak R, Goerdt S, Orfanos CE. Interferon alfa treatment of a patient with eosinophilic cellulitis and HIV infection. N Engl J Med 1997; 337:641.</a></li><li><a class="nounderline abstract_t">Diridl E, Hönigsmann H, Tanew A. Wells' syndrome responsive to PUVA therapy. Br J Dermatol 1997; 137:479.</a></li></ol></div><div id="topicVersionRevision">Topic 118663 Version 8.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5570262" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Recurrent granulomatous dermatitis with eosinophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3279079" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Wells' syndrome is a distinctive disease entity and not a histologic diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24421864" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Wells syndrome (eosinophilic cellulitis): Proposed diagnostic criteria and a literature review of the drug-induced variant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2606453" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Epithelioid haemangioma (angiolymphoid hyperplasia with eosinophilia) and Kimura's disease in Chinese.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2919716" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Lymphadenopathy of Kimura's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9263317" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Congenital Wells syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2004004" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Wells' syndrome in children: varicella infection as a precipitating event.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12869046" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Wells' syndrome following thiomersal-containing vaccinations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25395929" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Eosinophilic cellulitis (Wells' syndrome) caused by a temporary henna tattoo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14639411" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Eosinophilic fasciitis and eosinophilic cellulitis in a patient with abnormal circulating clonal T cells: increased production of interleukin 5 and inhibition by interferon alfa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9217826" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Wells' syndrome: a pathogenic role for circulating CD4+CD7- T cells expressing interleukin-5 mRNA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16551246" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The eosinophil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3760576" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Ribonuclease activity associated with human eosinophil-derived neurotoxin and eosinophil cationic protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3538819" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The eosinophilic leukocyte: structure and function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6206154" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Stimulation of basophil and rat mast cell histamine release by eosinophil granule-derived cationic proteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10215782" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Wells' syndrome (eosinophilic cellulitis): correlation between clinical activity, eosinophil levels, eosinophil cation protein and interleukin-5.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6347236" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Immunofluorescence identification of eosinophil granule major basic protein in the flame figures of Wells' syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/427009" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Eosinophilic cellulitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22150362" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Wells' syndrome associated with parvovirus in a 5-year old boy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29972218" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Wells' Syndrome Associated with Coxsackievirus A6 Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35261918" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Wells syndrome as a presenting sign of COVID-19 in the setting of allergic rhinitis and iron deficiency anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32304128" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Wells' syndrome related to Mycoplasma pneumoniae in a 5-year-old boy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10951158" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Wells' syndrome associated with recurrent giardiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19038064" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Febrile "migrating" eosinophilic cellulitis with hepatosplenomegaly: adult toxocariasis - a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2191801" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Wells' syndrome, insect bites, and eosinophils.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6512050" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Eosinophilic cellulitis (Wells' syndrome): histologic and clinical features in arthropod bite reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16631949" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Relapse of Wells' syndrome in a child after tetanus-diphtheria immunization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9268752" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Wells' syndrome related to tetanus vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29998475" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Pediatric Wells syndrome (eosinophilic cellulitis) after vaccination: A case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35522122" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Eosinophilic cellulitis in response to BNT162b2 COVID-19 vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34547138" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Eosinophilic cellulitis after BNT162b2 mRNA Covid-19 vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15995016" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Bullous "cellulitis" with eosinophilia: case report and review of Wells' syndrome in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16983003" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Wells syndrome in adults and children: a report of 19 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17576951" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Recurrent, pruritic dermal plaques and bullae. Diagnosis: eosinophilic cellulitis (Wells syndrome).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22019801" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Wells' syndrome (eosinophilic cellulitis) secondary to infliximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30685913" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Wells' Syndrome Induced by Ustekinumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29240526" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Wells syndrome secondary to influenza vaccination: A case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32034766" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Wells syndrome (eosinophilic cellulitis) following vaccination: Two pediatric cases with positive patch test to aluminium salts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24945651" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Recurrent paraneoplastic wells syndrome in a patient with metastatic renal cell cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30063068" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Case of Wells' syndrome: A rare association with the clinical course of chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23923089" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Flame figures associated with eosinophilic dermatosis of hematologic malignancy: is it possible to distinguish the condition from eosinophilic cellulitis in patients with hematoproliferative disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25846461" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : [Wells Syndrome in children and atopy: Retrospective study of 11 cases and review of the literature].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9631998" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Familial eosinophilic cellulitis, dysmorphic habitus, and mental retardation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23730155" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Diagnosis and management of eosinophilic cellulitis (Wells' syndrome): A case series and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31995962" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Erysipelas-like presentation of Wells' syndrome (eosinophilic cellulitis).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3422853" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Eosinophilic cellulitis in a family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20652113" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Wells Syndrome with Multiorgan Involvement Mimicking Hypereosinophilic Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15672727" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : [A case of eosinophilic cellulitis (Wells' syndrome)].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7593797" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Wells' syndrome in childhood: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7259222" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Eosinophilic cellulitis. (Well's syndrome) in a child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21779422" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Wells syndrome (eosinophilic cellulitis): a clinical imitator of bacterial cellulitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15324388" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Cutaneous adverse reaction to 2-chlorodeoxyadenosine with histological flame figures in patients with chronic lymphocytic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3728877" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Eosinophilic infiltration with flame figures. A distinctive tissue reaction seen in Wells' syndrome and other diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12581147" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Wells' syndrome: a clinical and histopathologic review of seven cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2426897" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The histopathogenesis of the flame figure in Wells' syndrome based on five cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15630108" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Narrative review: diseases that masquerade as infectious cellulitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6727934" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Episodic angioedema associated with eosinophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25527564" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Episodic angioedema with eosinophilia (Gleich syndrome) is a multilineage cell cycling disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29101481" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Eosinophilic Fasciitis: an Updated Review on Diagnosis and Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10606056" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Insect bite-like reaction in patients with hematologic malignant neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22612903" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Eosinophilic dermatosis of hematologic malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30528498" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Eosinophilic dermatosis of hematologic malignancy: A retrospective cohort of 37 patients from an Italian center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34265409" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Overexpression of helper T cell type 2-related molecules in the skin of patients with eosinophilic dermatosis of hematologic malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27357601" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Treatment of eosinophilic cellulitis (Wells syndrome) - a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2589856" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Low-dose alternate-day prednisone for persistent Wells' syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10430002" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Eosinophilic cellulitis in a child successfully treated with cetirizine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32713149" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Effective treatment with mepolizumab in a patient with refractory Wells syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32578132" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Mepolizumab Therapy for Recalcitrant Eosinophilic Annular Erythema in an Adult: A Case Report and Review of Treatment Options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29892672" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Eosinophilic cellulitis (Wells syndrome) successfully treated with mepolizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31530507" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Long-term Remission of Wells Syndrome With Omalizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34549522" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Dupilumab in eosinophilic cellulitis (Wells' syndrome) - case report of a potential new treatment option.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11641541" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Eosinophilic cellulitis (Wells' syndrome) successfully treated with low-dose cyclosporine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7406784" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Eosinophilic cellulitis--a response to treatment with dapsone: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20952936" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Eosinophilic cellulitis - A case study and management with griseofulvin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9534905" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Eosinophilic cellulitis (Wells' syndrome): treatment with minocycline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1498377" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Wells' syndrome: report of 2 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9280840" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Interferon alfa treatment of a patient with eosinophilic cellulitis and HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9349363" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Wells' syndrome responsive to PUVA therapy.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
